Regorafenib (BAY 73-4506)

Name: Regorafenib (BAY 73-4506)
Brand: Selleck Chemicals
SKU: S1178
Rating: 5 (137 reviews)

For research use only.

Catalog No.S1178 Synonyms: Fluoro-Sorafenib, Resihance, Stivarga

137 publications

Regorafenib (BAY 73-4506) Chemical Structure

CAS No. 755037-03-7

Regorafenib (BAY 73-4506, Fluoro-Sorafenib, Resihance, Stivarga) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit (c-Kit), RET (c-RET) and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM in cell-free assays, respectively. Regorafenib induces autophagy.

Selleck's Regorafenib (BAY 73-4506) has been cited by 137 publications

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Gastroenterology, 2017, 153(4):1082-1095

PubMed: 28625833 ( click the link to review the publication )

Neoplasia, 2021, 23(3):304-325

PubMed: 33582407 ( click the link to review the publication )

Mol Cancer Res, 2021, molcanres.0808.2020

PubMed: 33980612 ( click the link to review the publication )

Front Pharmacol, 2021, 12:632201

PubMed: 34220494 ( click the link to review the publication )

PLoS One, 2021, 16(7):e0253258

PubMed: 34234354 ( click the link to review the publication )

Int J Mol Sci, 2021, 22(3)1502

PubMed: 33540939 ( click the link to review the publication )

Food Funct, 2021, 10.1039/d0fo02270e

PubMed: 33570057 ( click the link to review the publication )

Cancer Res, 2020, 80(21):4815-4827

PubMed: 32907836 ( click the link to review the publication )

Cancers (Basel), 2020, 12(12)E3816

PubMed: 33348809 ( click the link to review the publication )

Front Oncol, 2020, 10:878

PubMed: 32582546 ( click the link to review the publication )

Front Oncol, 2020, 10:563249

PubMed: 33072590 ( click the link to review the publication )

Antiviral Res, 2020, 178:104790

PubMed: 32272175 ( click the link to review the publication )

Arthritis Res Ther, 2020, 22(1):160

PubMed: 32586377 ( click the link to review the publication )

Int J Mol Sci, 2020, 18;21(8):2825

PubMed: 32325639 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Front Oncol, 2020, 10:694

PubMed: 32670862 ( click the link to review the publication )

Int J Radiat Biol, 2020, 2:1-12

PubMed: 32052681 ( click the link to review the publication )

Front Oncol, 2020, 10:291

PubMed: 32195190 ( click the link to review the publication )

Biochem Biophys Res Commun, 2020, 529(3):699-706

PubMed: 32736695 ( click the link to review the publication )

Onco Targets Ther, 2020, 13:7213-7227

PubMed: 32801751 ( click the link to review the publication )
Nat Cell Biol, 2019, 21(2):203-213

PubMed: 30664786 ( click the link to review the publication )

Gut, 2019, 10.1136/gutjnl-2019-318506

PubMed: 31519701 ( click the link to review the publication )

Cell Rep, 2019, 29(3):573-588

PubMed: 31618628 ( click the link to review the publication )

Br J Pharmacol, 2019, 176(6):787-800

PubMed: 30592786 ( click the link to review the publication )

EBioMedicine, 2019, 41:175-184

PubMed: 30765319 ( click the link to review the publication )

J Med Chem, 2019, 10.1021/acs.jmedchem.9b00855

PubMed: 31364850 ( click the link to review the publication )

Cancers (Basel), 2019, 11(4)

PubMed: 31018508 ( click the link to review the publication )

Cell Death Dis, 2019, 10(10):784

PubMed: 31611551 ( click the link to review the publication )

Cell Death Dis, 2019, 10(9):672

PubMed: 31511501 ( click the link to review the publication )

Br J Cancer, 2019, 120(6):612-620

PubMed: 30792533 ( click the link to review the publication )

Cell Chem Biol, 2019, 10.1016/j.chembiol.2019.04.011

PubMed: 31155509 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(11):2146-2157

PubMed: 31439713 ( click the link to review the publication )

Cell Commun Signal, 2019, 17(1):85

PubMed: 31349793 ( click the link to review the publication )

Sci Rep, 2019, 9(1):636

PubMed: 30679688 ( click the link to review the publication )

Sci Rep, 2019, 9(1):7103

PubMed: 31068603 ( click the link to review the publication )

Cell Biosci, 2019, 9:88

PubMed: 31673329 ( click the link to review the publication )

Molecules, 2019, 24(7)

PubMed: 30959969 ( click the link to review the publication )

BMC Microbiol, 2019, 19(1):34

PubMed: 30736730 ( click the link to review the publication )

Dis Markers, 2019, 2019:8964015

PubMed: 31781310 ( click the link to review the publication )

FEBS Open Bio, 2019, 9(2):335-347

PubMed: 30761258 ( click the link to review the publication )

Ann Biomed Eng, 2019, 10.1007/s10439-019-02269-2

PubMed: 31020445 ( click the link to review the publication )

Nat Metab, 2019, 1(10):985-995

PubMed: 32021964 ( click the link to review the publication )

Animal Model Exp Med, 2019, 2(4):259-268

PubMed: 31942558 ( click the link to review the publication )

Ann Surg Oncol, 2019, 26(1):139-147

PubMed: 30414038 ( click the link to review the publication )
Mol Cancer Ther, 2018, 17(12):2610-2621

PubMed: 30224431 ( click the link to review the publication )

Endocr Relat Cancer, 2018, 25(4):471-480

PubMed: 29440231 ( click the link to review the publication )

Cancer Sci, 2018, 109(11):3591-3601

PubMed: 30142229 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 504(4):878-884

PubMed: 30219235 ( click the link to review the publication )

Anticancer Res, 2018, 38(4):1967-1977

PubMed: 29599312 ( click the link to review the publication )

Chem Sci, 2018, 9(10):2674-2689

PubMed: 29732051 ( click the link to review the publication )

Oncotarget, 2018, 9(56):30869-30882

PubMed: 30112114 ( click the link to review the publication )

BMC Res Notes, 2018, 11(1):859

PubMed: 30514372 ( click the link to review the publication )

Sci Transl Med, 2017, 14;9(394):eaah6144

PubMed: 28615362 ( click the link to review the publication )

Cancer Res, 2017, 77(9):2512-2521

PubMed: 28202514 ( click the link to review the publication )

Arch Toxicol, 2017, 91(8):2921-2938

PubMed: 28032146 ( click the link to review the publication )

Mol Biol Cell, 2017, 28(7):907-921

PubMed: 28209733 ( click the link to review the publication )

Toxicol Sci, 2017, 158(1):213-226

PubMed: 28453775 ( click the link to review the publication )

Sci Rep, 2017, 7(1):1502

PubMed: 28473715 ( click the link to review the publication )

Molecules, 2017, 22(12)

PubMed: 29206199 ( click the link to review the publication )

PLoS One, 2017, 12(3):e0174151

PubMed: 28301591 ( click the link to review the publication )

Curr Cancer Drug Targets, 2017, 17(4):386-401

PubMed: 27396604 ( click the link to review the publication )

Naunyn Schmiedebergs Arch Pharmacol, 2017, 390(11):1125-1134

PubMed: 28779210 ( click the link to review the publication )

Med Sci Monit, 2017, 23:1963-1972

PubMed: 28435150 ( click the link to review the publication )

J Mol Graph Model, 2017,

PubMed: 28236743 ( click the link to review the publication )

Exp Ther Med, 2017, 14(2):1357-1366

PubMed: 28810597 ( click the link to review the publication )

Oncotarget, 2017, 8(4):6102-6113

PubMed: 28008149 ( click the link to review the publication )

Oncotarget, 2017, 8(61):104090-104103

PubMed: 29262623 ( click the link to review the publication )

Oncotarget, 2017, 8(61):103465-103476

PubMed: 29262576 ( click the link to review the publication )
Oncotarget, 2017, 8(69):113444-113459

PubMed: 29371921 ( click the link to review the publication )

Oncotarget, 2017, 8(47):83052-83062

PubMed: 29137323 ( click the link to review the publication )

Oncotarget, 2017, 9(3):3605-3618

PubMed: 29423069 ( click the link to review the publication )

Oncotarget, 2017, 8(52):90262-90277

PubMed: 29163826 ( click the link to review the publication )

Oncotarget, 2017, 8(59):99451-99469

PubMed: 29245915 ( click the link to review the publication )

Oncotarget, 2017, 8(1):1449-1468

PubMed: 27903966 ( click the link to review the publication )

Oncotarget, 2017, 9(17):13154-13166

PubMed: 29568347 ( click the link to review the publication )

Oncotarget, 2017, 8(50):87209-87220

PubMed: 29152075 ( click the link to review the publication )

Oncotarget, 2017, 8(12):18832-18847

PubMed: 27902968 ( click the link to review the publication )

Oncotarget, 2017, 8(10):16367-16386

PubMed: 28146421 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 29137323 ( click the link to review the publication )

Oncotarget, 2017, 8(69):113444-113459

PubMed: 29371921 ( click the link to review the publication )

ACS Nano, 2016, 10(11):9999-10012

PubMed: 27934069 ( click the link to review the publication )

Cancer Res, 2016, 76(1):117-26

PubMed: 26677977 ( click the link to review the publication )

Oncogene, 2016, 10.1038/onc.2016.247

PubMed: 27399335 ( click the link to review the publication )

PLoS Genet, 2016, 12(9):e1006279

PubMed: 27588951 ( click the link to review the publication )

Bioinformatics, 2016, 32(12):i253-i261

PubMed: 27307624 ( click the link to review the publication )

ACS Chem Biol, 2016, 11(12):3400-3411

PubMed: 27768280 ( click the link to review the publication )

J Cell Physiol, 2016, 231(5):1097-105

PubMed: 26419617 ( click the link to review the publication )

Sci Rep, 2016, 6:35308

PubMed: 27752061 ( click the link to review the publication )

J Cell Physiol, 2016, 231(10):2286-302

PubMed: 27187154 ( click the link to review the publication )

Oncotarget, 2016, 7(18):26580-92

PubMed: 27058891 ( click the link to review the publication )

Oncotarget, 2016, 7(11):12975-96

PubMed: 26887051 ( click the link to review the publication )

Oncotarget, 2016, 7(14):17290-300

PubMed: 26981780 ( click the link to review the publication )
Oncotarget, 2016, 7(30):47954-47965

PubMed: 27323830 ( click the link to review the publication )

Oncotarget, 2016, 7(11):12975-96

PubMed: 26887051 ( click the link to review the publication )

Oncotarget, 2016, 7(26):40398-40417

PubMed: 27259258 ( click the link to review the publication )

EMBO Mol Med, 2015, 7(10):1350-65

PubMed: 26290450 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2015, 112(6):1839-44

PubMed: 25605917 ( click the link to review the publication )

Int J Cancer, 2015, 136(6):1434-44

PubMed: 25080865 ( click the link to review the publication )

J Exp Clin Cancer Res, 2015, 34:90

PubMed: 26329608 ( click the link to review the publication )

J Cell Physiol, 2015, 230(1):131-9

PubMed: 24911215 ( click the link to review the publication )

J Cell Physiol, 2015, 230(10):2552-78

PubMed: 25858032 ( click the link to review the publication )

J Cell Physiol, 2015, 10.1002/jcp.24961

PubMed: 25704960 ( click the link to review the publication )

Drug Metab Dispos, 2015, 43(12):1934-7

PubMed: 26443648 ( click the link to review the publication )

Cancer Biol Ther, 2015, 16(11):1660-70

PubMed: 26417912 ( click the link to review the publication )

Toxicology, 2015, 327:10-21

PubMed: 25445804 ( click the link to review the publication )

J Med Invest, 2015, 62(3-4):195-8

PubMed: 26399347 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 25909220 ( click the link to review the publication )

Oncotarget, 2015, 6(7):4745-56

PubMed: 25544765 ( click the link to review the publication )

Oncotarget, 2015, 6(30):28929-37

PubMed: 26078337 ( click the link to review the publication )

Oncotarget, 2015, 6(14):11820-32

PubMed: 25909220 ( click the link to review the publication )

Oncotarget, 2015, 6(27):23281-96

PubMed: 25966280 ( click the link to review the publication )

Gastroenterology, 2015, 148(7):1438-51

PubMed: 25754161 ( click the link to review the publication )

Oncotarget, 2015, 6(4):1954-66

PubMed: 25557174 ( click the link to review the publication )

Oncotarget, 2015, 6(16):14385-98

PubMed: 25965911 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26078337 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(22):5745-5755

PubMed: 25239608 ( click the link to review the publication )
Clin Cancer Res, 2014, 20(22):5768-76

PubMed: 25248379 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1278

PubMed: 24901049 ( click the link to review the publication )

Cancer Cell Int, 2014, 14(1):89

PubMed: 25253994 ( click the link to review the publication )

Cancer Biol Ther, 2014, 15(3):305-16

PubMed: 24351423 ( click the link to review the publication )

Toxicology, 2014, 10.1016/j.tox.2014.11.002

PubMed: ( click the link to review the publication )

Drug Des Devel Ther, 2014, 8:1107-23

PubMed: 25170251 ( click the link to review the publication )

Biomed Res Int, 2014, 2014:568693

PubMed: 25309914 ( click the link to review the publication )

Environ Mol Mutagen, 2014, 55(9):704-18

PubMed: 25111698 ( click the link to review the publication )

Mol Med Rep, 2014, 9(1):83-90

PubMed: 24213221 ( click the link to review the publication )

Oncotarget, 2014, 5(12):4071-86

PubMed: 24901229 ( click the link to review the publication )

Rostock University, 2014, Lange F

PubMed: ( click the link to review the publication )

Assay Drug Dev Technol, 2014, 12(9-10):514-26

PubMed: 25506801 ( click the link to review the publication )

J Clin Endocrinol Metab, 2013, 98(6):2502-12

PubMed: 23559083 ( click the link to review the publication )

Mol Pharmacol, 2013, 84(4):562-71

PubMed: 23877009 ( click the link to review the publication )

PLoS One, 2013, 8(5):e63240

PubMed: 23667592 ( click the link to review the publication )

J Interferon Cytokine Res, 2013, 33(4):211-25

PubMed: 23570388 ( click the link to review the publication )

Methods Mol Biol, 2011, 685:91-109

PubMed: 20981520 ( click the link to review the publication )

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description

Targets

RET ^[1] (Cell-free assay)	Raf-1 ^[1] (Cell-free assay)	VEGFR2 ^[1] (Cell-free assay)	Kit ^[1] (Cell-free assay)	VEGFR1 ^[1] (Cell-free assay)	View More
1.5 nM	2.5 nM	4.2 nM	7 nM	13 nM	View More

In vitro

Regorafenib strongly prevents VEGFR2 autophosphorylation in NIH-3T3/VEGFR2 cells with IC50 of 3 nM. In HAoSMCs, regorafenib suppress PDGFR-β autophosphorylation after stimulation with PDGF-BB, with an IC50 of 90 nM. Regorafenib also inhibits FGFR signaling in MCF-7 breast cancer (BC) cells stimulated with FGF10. Regorafenib very potently inhibited the mutant receptors KIT^K642E and RET^C634W, with IC50 of approximately 20 nM and 10 nM, respectively. Regorafenib inhibits the proliferation of VEGF¹⁶⁵-stimulated HUVECs, with an IC50 of approximately 3 nM. Regorafenib prevents the proliferation of FGF2-stimulated HUVECs and of PDGF-BB-stimulated HAoSMCs with IC50 of 127 nM and 146 nM, respectively. ^[1] Regorafenib targets both tumor cell proliferation and tumor vasculature through inhibition of receptors of tyrosine kinases (VEGFR, KIT, RET, FGFR, and PDGFR) and serine/threonine kinases (Raf and p38MAPK). ^[2] Regorafenib suppresses growth of human Hep3B, PLC/PRF/5 and HepG2 cells in a concentration- and time-dependent manner. ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Hep3B	MYDBdI9xfG:\|aYOgRZN{[Xl?	M4H0fFHjiJN3wrFOwG0>	MUK0PEBp		NYXPbJNOcW6qaXLpeJMh[2WubDDndo94fGh?	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN{OU[wPEc,OjZ\|Mkm2NFg9N2F-
PLC/PRF/5	M3\0R2Fxd3C2b4Ppd{BCe3OjeR?=	NUDDTm9OOeLCk{ZCpO69VQ>?	NWH5PY5nPDhiaB?=		NHz0fYNqdmirYnn0d{Bk\WyuIHfyc5d1cA>?	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN{OU[wPEc,OjZ\|Mkm2NFg9N2F-
HepG2	MkH1RZBweHSxc3nzJGF{e2G7	M1\UUFHjiJN3wrFOwG0>	Mlj5OFghcA>?		NGHvbIRqdmirYnn0d{Bk\WyuIHfyc5d1cA>?	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN{OU[wPEc,OjZ\|Mkm2NFg9N2F-
HEK293	M1fiTmZ2dmO2aX;uJGF{e2G7	M4rob\|AvPeLCid88US=>	MmHmNk81NzZiaB?=		NGDhb3Zz\WS3Y3XzJGdTWDd6IHX4dJJme3Orb36=	NHTUZlA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi1PFA{Oid-MkW4OVgxOzJ:L3G+
GEO	MlrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGfPUW4xNjBzLUKwJO69VQ>?	Mn3tPVYhcA>?	Mm\ISG1UVw>?	NXHnVGRXcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh\|OEO5NUc,OjV6M{izPVE9N2F-
SW48	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX[wMlAyNTJyIN88US=>	NGfU[4U6PiCq	NFnoOFNFVVOR	M2H0N4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	M4XXS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEO4N\|kyLz5{NUizPFM6OTxxYU6=
HT29	M4PwW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUTpcZA3OC5yMT2yNEDPxE1?	M3rTPVk3KGh?	NIC2WHdFVVOR	NWTxdWRjcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	NY\DPVVtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4N\|g{QTFpPkK1PFM5OzlzPD;hQi=>
SW480	NHzIVXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M130[VAvODFvMkCg{txO	MVu5OkBp	NYLBOWltTE2VTx?=	MkLwbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	Mm\IQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6M{izPVEoRjJ3OEO4N\|kyRC:jPh?=
SW620	NEThUYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NG\EXIkxNjBzLUKwJO69VQ>?	M{C0Rlk3KGh?	MlvhSG1UVw>?	NUXYR45DcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	NUDTcY95RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4N\|g{QTFpPkK1PFM5OzlzPD;hQi=>
HCT116	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mm\SNE4xOS1{MDFOwG0>	Mn\lPVYhcA>?	M4XxOGROW09?	NV3iZ\|R2cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	MnPxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6M{izPVEoRjJ3OEO4N\|kyRC:jPh?=
LOVO	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVOwMlAyNTJyIN88US=>	MV25OkBp	NHnkV29FVVOR	NHf1W3hqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh\|OEO5NUc,OjV6M{izPVE9N2F-
HCT150	M1vNe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXr6bmVlOC5yMT2yNEDPxE1?	MnvFPVYhcA>?	NF7EZVFFVVOR	NILxcoVqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	NIDBSmg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUizPFM6OSd-MkW4N\|g{QTF:L3G+
SW48-CR	M16xVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV;sR5kxOC5yMT2yNEDPxE1?	MojXPVYhcA>?	NEHXVIpFVVOR	M{LDZ4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	MlOyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6M{izPVEoRjJ3OEO4N\|kyRC:jPh?=
GEO-CR	M4m0b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHvObnQxNjBzLUKwJO69VQ>?	MnzrPVYhcA>?	NX\CeVZ3TE2VTx?=	MoPQbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh\|OEO5NUc,OjV6M{izPVE9N2F-
KB-31	NWD1V3JUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWLRNYFTUUN3ME21MlXDuTBwMzDuUS=>	MmLuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NUOzOlEoRjJ3N{WzN\|YyRC:jPh?=
KB-G2	NEi0fYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVezNXF4UUN3ME25MlHDuTBwMTDuUS=>	NETZeVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe1N\|M3OSd-MkW3OVM{PjF:L3G+
LLC-PK1	NV\N[XZwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXnJR\|UxRTR{LkFCtVMvOiCwTR?=	NH20UGk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe1N\|M3OSd-MkW3OVM{PjF:L3G+
LLC-PK1/MRP2	MkLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn3ZTWM2OD16Mj60xtEzNjdibl2=	M{fpPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{WzN\|YyLz5{NUe1N\|M3OTxxYU6=
HEK293	M{Xz[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWrJR\|UxRTFzLkFCtVEvOiCwTR?=	NV74d2lFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OVM{PjFpPkK1O\|U{OzZzPD;hQi=>
HEK293/OATP1B1	NYfUfYlQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWfpb3I2UUN3ME22MlLDuTBwMzDuUS=>	NIf4VZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe1N\|M3OSd-MkW3OVM{PjF:L3G+
HROC18	NITJdWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mon3TWM2OD1zLkOg{txO	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTNyOUmxOEc,OjV\|MEm5NVQ9N2F-
HROC24	M2PXdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHrHboxKSzVyPUSuOkDPxE1?	NIr3V4o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUOwPVkyPCd-MkWzNFk6OTR:L3G+
HROC43	NEPQ[ZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2DUcGlEPTB;NT6zJO69VQ>?	M1K1RVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{C5PVE1Lz5{NUOwPVkyPDxxYU6=
HROC46	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGPjSVhKSzVyPUKuOEDPxE1?	NX;KZox3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzNFk6OTRpPkK1N\|A6QTF2PD;hQi=>
RJ345	M1HW[WZ2dmO2aX;uJGF{e2G7	NXyxTFB1OC53L{Wg{txO	NG[yTmIzPCCq	MnXVSG1UVw>?	MVnpcohq[mm2czD0bIUh[2WubDDtbYdz[XSrb36=	NILx[Wo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK1N\|k6PCd-MkWyOVM6QTR:L3G+
RJ348	NFj1XGtHfW6ldHnvckBCe3OjeR?=	NHrWWJcxNjVxNTFOwG0>	MWSyOEBp	NWDtdFdmTE2VTx?=	MXLpcohq[mm2czD0bIUh[2WubDDtbYdz[XSrb36=	M1zJNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkWzPVk1Lz5{NUK1N\|k6PDxxYU6=
MCF-7	M17vVGZ2dmO2aX;uJGF{e2G7	NUm0NJhJOC53L{Wg{txO	NWD5PZBKOjRiaB?=	MX3EUXNQ	MXjpcohq[mm2czD0bIUh[2WubDDtbYdz[XSrb36=	M{TV[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkWzPVk1Lz5{NUK1N\|k6PDxxYU6=
MDA-MB-231	MnnRSpVv[3Srb36gRZN{[Xl?	NH3XR4oxNjVxNTFOwG0>	MY[yOEBp	NUf6RXRYTE2VTx?=	MUfpcohq[mm2czD0bIUh[2WubDDtbYdz[XSrb36=	NHW3e5Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK1N\|k6PCd-MkWyOVM6QTR:L3G+
HT15	NX\ITIU{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWrteoZ3OS1{MDFOwG0>	NH7lOWY1QCCq		MXfpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB5MUCxPEc,OjVyN{GwNVg9N2F-
DLD1	NWrzcWlzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUDxNJJiOS1{MDFOwG0>	NEP1fII1QCCq		MWXpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	MkLvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyN{GwNVgoRjJ3MEexNFE5RC:jPh?=
HT-29	M13QNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn7KNU0zOCEQvF2=	MnfYOFghcA>?		M2LueolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	MlHnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyN{GwNVgoRjJ3MEexNFE5RC:jPh?=
Hct-116	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWSxMVIxKM7:TR?=	MmC3OFghcA>?		NYT2enhQcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	M3PxeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEexNFE5Lz5{NUC3NVAyQDxxYU6=
HT15	NHK5fopCeG:ydH;zbZMhSXO\|YYm=	NYfjXoM3OS1zMDFOwG0>	M13aTlQ5KGh?		NEe1OpFqdmS3Y3XzJINmdGxiZHXheIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	M{\KVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEexNFE5Lz5{NUC3NVAyQDxxYU6=
DLD1	NHXC[WpCeG:ydH;zbZMhSXO\|YYm=	M3\YXVEuOTBizszN	MljGOFghcA>?		M3v4V4lv\HWlZYOgZ4VtdCCmZXH0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB5MUCxPEc,OjVyN{GwNVg9N2F-
HT-29	NVPic2g{SXCxcITvd4l{KEG\|c3H5	M162UlEuOTBizszN	M2jDblQ5KGh?		MWTpcoR2[2W\|IHPlcIwh\GWjdHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	Mom3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyN{GwNVgoRjJ3MEexNFE5RC:jPh?=
Hct-116	MX\BdI9xfG:\|aYOgRZN{[Xl?	MXOxMVExKM7:TR?=	NX25XlRHPDhiaB?=		M2\Oe4lv\HWlZYOgZ4VtdCCmZXH0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	NUiz[3pVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwO\|ExOThpPkK1NFcyODF6PD;hQi=>
GBM5	NV;Eb4NISXCxcITvd4l{KEG\|c3H5	M1vwRVAvPeLCk{GuNQKBkc7:TR?=	NHrLb\|AzPCCq	MmjlSG1UVw>?	MX;pcpRmemGldIOge4l1cCCuYYDheIlvcWJidH:gbY5lfWOnIHPlcIwh\GWjdHi=	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlzMUKxOUc,OjR7MUGyNVU9N2F-
GBM6	MYDBdI9xfG:\|aYOgRZN{[Xl?	NWDxRlh7OC534pETNU4x6oDLzszN	MX:yOEBp	MXTEUXNQ	M3z6WYlvfGW{YXP0d{B4cXSqIHzhdIF1cW6rYjD0c{BqdmS3Y3WgZ4VtdCCmZXH0bC=>	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlzMUKxOUc,OjR7MUGyNVU9N2F-
GBM12	MlLKRZBweHSxc3nzJGF{e2G7	M3\BVlAvPeLCk{GuNQKBkc7:TR?=	M3exd\|I1KGh?	NUi2TWFJTE2VTx?=	M36yXIlvfGW{YXP0d{B4cXSqIHzhdIF1cW6rYjD0c{BqdmS3Y3WgZ4VtdCCmZXH0bC=>	NGjTPHA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmxNVIyPSd-MkS5NVEzOTV:L3G+
GBM14	M{K1N2Fxd3C2b4Ppd{BCe3OjeR?=	M13mNlAvPeLCk{GuNQKBkc7:TR?=	NFS4NHIzPCCq	NVjMW\|h7TE2VTx?=	MoPqbY51\XKjY4TzJJdqfGhibHHwZZRqdmmkIITvJIlv\HWlZTDj[YxtKGSnYYTo	NGH1bFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmxNVIyPSd-MkS5NVEzOTV:L3G+
Hep3B	MoLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3fqdFHjiJN{LkZCpO69VQ>?	MYSyOE81QC95MjDo		M33OPIlvcGmkaYTzJINmdGxiZ4Lve5Rp	NV\KUJd4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4PFU5QTBpPkK0PFg2QDlyPD;hQi=>
PLC/PRF/5	NGrxNIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1nqclHjiJN{LkZCpO69VQ>?	MYGyOE81QC95MjDo		MWHpcohq[mm2czDj[YxtKGe{b4f0bC=>	NG\5UGo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi4OVg6OCd-MkS4PFU5QTB:L3G+
HepG2	NW[yO3NyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUWx5qCUOi53wrFOwG0>	NF;TNVkzPC92OD:3NkBp		NEC4OFFqdmirYnn0d{Bk\WyuIHfyc5d1cA>?	MkHoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6OEW4PVAoRjJ2OEi1PFkxRC:jPh?=
HCT116	MWPGeY5kfGmxbjDBd5NigQ>?	MlvXNVAwOjBxNECg{txO	NUHFR5JiOjRiaB?=		MnrEbY5lfWOnczDQWW1CKHC{b4TlbY4h[W6mIH3SUmEh\XiycnXzd4lwdiCrbjDhJIRwe2VvIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ?	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd4M{[xNUc,OjR5NkO2NVE9N2F-
Lim2405	NITGcZdHfW6ldHnvckBCe3OjeR?=	M1jRWVQxKM7:TR?=	M3SzPVI1KGh?		NXSzO3Z6cW6mdXPld{BRXU2DIIDyc5RmcW5iYX7kJINmdGxiYYDvdJRwe2m\|	NUC0[5FYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3OlM3OTFpPkK0O\|Y{PjFzPD;hQi=>
LoVo	NWXTVpdCTnWwY4Tpc44hSXO\|YYm=	Mm\EOFAh\|ryP	NHXYO\|UzPCCq		M3niTYlv\HWlZYOgVHVOSSCycn;0[YlvKGGwZDDj[YxtKGGyb4D0c5Nqew>?	NXXaSpFuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3OlM3OTFpPkK0O\|Y{PjFzPD;hQi=>
Lim1215	NUH3cYZMTnWwY4Tpc44hSXO\|YYm=	M2LvXFQxKM7:TR?=	MmjLNlQhcA>?		NGXJU3NqdmS3Y3XzJHBWVUFicILveIVqdiCjbnSgZ4VtdCCjcH;weI9{cXN?	M4nLdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{[zOlEyLz5{NEe2N\|YyOTxxYU6=
SW48	MlfZSpVv[3Srb36gRZN{[Xl?	MkXvOFAh\|ryP	MVmyOEBp		M4nBSIlv\HWlZYOgVHVOSSCycn;0[YlvKGGwZDDj[YxtKGGyb4D0c5Nqew>?	NHzsb4g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe2N\|YyOSd-MkS3OlM3OTF:L3G+
RKO	MVfGeY5kfGmxbjDBd5NigQ>?	NHraVIk1OCEQvF2=	MlXxNlQhcA>?		MUDpcoR2[2W\|IGDVUWEheHKxdHXpckBidmRiY3XscEBieG:ydH;zbZM>	M{XPT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{[zOlEyLz5{NEe2N\|YyOTxxYU6=
SW837	Ml;2SpVv[3Srb36gRZN{[Xl?	NFXRR4E1OCEQvF2=	MmHMNlQhcA>?		MmnsbY5lfWOnczDQWW1CKHC{b4TlbY4h[W6mIHPlcIwh[XCxcITvd4l{	NH25dJo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe2N\|YyOSd-MkS3OlM3OTF:L3G+
SW1463	NUHjNVV5TnWwY4Tpc44hSXO\|YYm=	MVy0NEDPxE1?	MUGyOEBp		NXW4VldXcW6mdXPld{BRXU2DIIDyc5RmcW5iYX7kJINmdGxiYYDvdJRwe2m\|	NU\lOGJIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3OlM3OTFpPkK0O\|Y{PjFzPD;hQi=>
SW480	M{jaOWZ2dmO2aX;uJGF{e2G7	NHLVNGs1OCEQvF2=	Mof2NlQhcA>?		NVXXOG5FcW6mdXPld{BRXU2DIIDyc5RmcW5iYX7kJINmdGxiYYDvdJRwe2m\|	M3nMXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{[zOlEyLz5{NEe2N\|YyOTxxYU6=
Vaco432	NIDVXZFHfW6ldHnvckBCe3OjeR?=	NIDtVoI1OCEQvF2=	M2rhZlI1KGh?		MkXibY5lfWOnczDQWW1CKHC{b4TlbY4h[W6mIHPlcIwh[XCxcITvd4l{	M33BOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{[zOlEyLz5{NEe2N\|YyOTxxYU6=
Vaco400	NIjYSJNHfW6ldHnvckBCe3OjeR?=	MVu0NEDPxE1?	MViyOEBp		NGfUZYdqdmS3Y3XzJHBWVUFicILveIVqdiCjbnSgZ4VtdCCjcH;weI9{cXN?	M2\JWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{[zOlEyLz5{NEe2N\|YyOTxxYU6=
DLD1	MUjGeY5kfGmxbjDBd5NigQ>?	NU\jPWozPDBizszN	M{jEWVI1KGh?		MUDpcoR2[2W\|IGDVUWEheHKxdHXpckBidmRiY3XscEBieG:ydH;zbZM>	Mln0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5NkO2NVEoRjJ2N{[zOlEyRC:jPh?=
HT29	NUi4TXVVTnWwY4Tpc44hSXO\|YYm=	MXe0NEDPxE1?	NVzEOZhDOjRiaB?=		MkHBbY5lfWOnczDQWW1CKHC{b4TlbY4h[W6mIHPlcIwh[XCxcITvd4l{	MnvzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5NkO2NVEoRjJ2N{[zOlEyRC:jPh?=
PLC/PRF/5	NWLMXJkyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{WxXVHjiJN3wsXN	MmrFNlQwPDhxN{KgbC=>		M3;TRolvcGmkaYTzJINmdGxiZ4Lve5Rp	NIW0SlY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{G2PVE1QCd-MkOxOlkyPDh:L3G+
HepG2	NV;NPVZxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnewNgKBmzYEtV2=	MX2yOE81QC95MjDo		M2T4dYlvcGmkaYTzJINmdGxiZ4Lve5Rp	NF31bXg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{G2PVE1QCd-MkOxOlkyPDh:L3G+
Hep3B	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUKx5qCUPcL3TR?=	MmfPNlQwPDhxN{KgbC=>		MYPpcohq[mm2czDj[YxtKGe{b4f0bC=>	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzF4OUG0PEc,OjNzNkmxOFg9N2F-
BA/F3	NWXDNnZqT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MlW0O\|IhcHK\|		Mn\1TY5pcWKrdHnvckBw\iCNaYSg[ZhwdiBzMTDk[YxmfGmxbjCoOVU4KHSxIEW1PEBz\XOrZIXld{khdXW2YX70JEh2dmuwb4fuJI9zcWerbjmgeJJidnOoZXP0[YQhcW5ibX;1d4UhSkFxRkOgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iClZXzsJIdzd3e2aDDpcoN2[mG2ZXSg[o9zKDd{IHjyd{BjgSCPVGOgZZN{[XluIFfJOVAhRSByLkCyNUDPxE1w	NGL2SGY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEKwOFQ1OSd-M{CyNFQ1PDF:L3G+
BA/F3	MmXsS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NXjINWpUPzJiaILz		NXK4RZRGUW6qaXLpeIlwdiCxZjDUSWwu\nW\|ZXSgVGRITlKkZYThJEh2dmuwb4fuJI9zcWerbjmgeJJidnOoZXP0[YQhcW5ibX;1d4UhSkFxRkOgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iClZXzsJIdzd3e2aDDpcoN2[mG2ZXSg[o9zKDd{IHjyd{BjgSCPVGOgZZN{[XluIFfJOVAhRSByLkCyPUDPxE1w	NEe3OmU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEKwOFQ1OSd-M{CyNFQ1PDF:L3G+
BA/F3	MVjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		Mn\EO\|IhcHK\|		NGrJT3RKdmirYnn0bY9vKG:oIFvpeEBmgG:wIEGxJIRmdGW2aX;uJEg2PTdidH:gOVU5KHKnc3nkeYV{MSCjbnSgSFgyPkhibYX0ZY51KGGwZDDUOlcxUSCvdYThcpQhMHWwa37ve44hd3KrZ3nuLUB1emGwc3\lZ5Rm\CCrbjDtc5V{\SCEQT;GN{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHPlcIwh\3Kxd4ToJIlv[3WkYYTl[EBnd3JiN{KgbJJ{KGK7IF3UV{Bie3OjeTygS2k2OCB;IECuNFM{KM7:TT6=	MkHQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB{MES0OFEoRjNyMkC0OFQyRC:jPh?=
BA/F3	NGj4bVNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NYSxfZZWPzJiaILz		M{nPdGlvcGmkaYTpc44hd2ZiS3n0JIV5d25iMUGg[IVt\XSrb36gLFU2PyC2bzC1OVghemW\|aXT1[ZMqKGGwZDDBPFI6WCCvdYThcpQh[W6mIGm4NlNFKG23dHHueEApfW6tbn;3ckBwemmpaX6pJJRz[W6\|ZnXjeIVlKGmwIH3veZNmKEKDL1[zJINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiY3XscEBoem:5dHigbY5kfWKjdHXkJIZweiB5MjDodpMh[nliTWTTJIF{e2G7LDDHTVUxKD1iMD6wOFch\|ryPLh?=	NHTiZ5k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEKwOFQ1OSd-M{CyNFQ1PDF:L3G+
BA/F3	Mk[0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MWS3NkBpenN?		NIfoOIhKdmirYnn0bY9vKG:oIFvpeEBmgG:wIEGxJIRmdGW2aX;uJEg2PTdidH:gOVU5KHKnc3nkeYV{MSCjbnSgUlgzOktibYX0ZY51KGGwZDDZPFI{TCCvdYThcpQhMHWwa37ve44hd3KrZ3nuLUB1emGwc3\lZ5Rm\CCrbjDtc5V{\SCEQT;GN{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHPlcIwh\3Kxd4ToJIlv[3WkYYTl[EBnd3JiN{KgbJJ{KGK7IF3UV{Bie3OjeTygS2k2OCB;IECuNFQ6KM7:TT6=	NITLblY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEKwOFQ1OSd-M{CyNFQ1PDF:L3G+
BA/F3	M1XiPWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MmrCO\|IhcHK\|		M1XQXGlvcGmkaYTpc44hd2ZiVFXMMYZ2e2WmIGDES2ZT[WyyaHGgLJVvc26xd36gc5Jq\2mwKTD0doFve2[nY4Tl[EBqdiCvb4Xz[UBDSS:IMzDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGOnbHyg[5Jwf3SqIHnuZ5Vj[XSnZDDmc5IhPzJiaILzJIJ6KE2WUzDhd5NigSxiR1m1NEA:KDBwMEWxJO69VS5?	NVGwfZJPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CyNFQ1PDFpPkOwNlA1PDRzPD;hQi=>
BA/F3	M{PnbGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M{TseVczKGi{cx?=		NGPOOoxKdmirYnn0bY9vKG:oIFvpeEBmgG:wIEGxJIRmdGW2aX;uJEg2PTdidH:gOVU5KHKnc3nkeYV{MSCjbnSgSFgzOEFibYX0ZY51KGGwZDDEPFIxSSCvdYThcpQhMHWwa37ve44hd3KrZ3nuLUB1emGwc3\lZ5Rm\CCrbjDtc5V{\SCEQT;GN{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHPlcIwh\3Kxd4ToJIlv[3WkYYTl[EBnd3JiN{KgbJJ{KGK7IF3UV{Bie3OjeTygS2k2OCB;IECuNFY{KM7:TT6=	Mnm2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB{MES0OFEoRjNyMkC0OFQyRC:jPh?=
BA/F3	NUmzS3l1T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M1zZcVczKGi{cx?=		NYfISWFCUW6qaXLpeIlwdiCxZjDLbZQh\XixbjCxNUBl\WyndHnvckApPTV5IITvJFU2QCC{ZYPp[JVmeyliYX7kJHk5OjOGIH31eIFvfCBqdX7rco94diCxcnnnbY4qKHS{YX7z[oVkfGWmIHnuJI1wfXOnIFLBM2Y{KGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[gZ4VtdCCpcn;3eIghcW6ldXLheIVlKG[xcjC3NkBpenNiYomgUXRUKGG\|c3H5MEBIUTVyIE2gNE4xQTRizszNMi=>	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODJyNES0NUc,OzB{MES0OFE9N2F-
BA/F3	NFflTWJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M{XDPFczKGi{cx?=		M3HTZWlvcGmkaYTpc44hd2ZiS3n0JHY2PjCGIH31eIFvfCBqdX7rco94diCxcnnnbY4qKHS{YX7z[oVkfGWmIHnuJI1wfXOnIFLBM2Y{KGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[gZ4VtdCCpcn;3eIghcW6ldXLheIVlKG[xcjC3NkBpenNiYomgUXRUKGG\|c3H5MEBIUTVyIE2gNE4yODhizszNMi=>	NWDRVo5DRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CyNFQ1PDFpPkOwNlA1PDRzPD;hQi=>
BA/F3	NUPkeY5ET3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NGPpXYs4OiCqcoO=		NXXQfYV4UW6qaXLpeIlwdiCxZjDLbZQh\XixbjC5JGF[PTB{IITvJFUxOyCrboPldpRqd25ibYX0ZY51KCi3bnvuc5dvKG:{aXfpckkhfHKjboPm[YN1\WRiaX6gcY92e2ViQlGvSlMh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDj[YxtKGe{b4f0bEBqdmO3YnH0[YQh\m:{IEeyJIhzeyCkeTDNWHMh[XO\|YYmsJGdKPTBiPTCwMlEyPCEQvF2u	NWj5UXFwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CyNFQ1PDFpPkOwNlA1PDRzPD;hQi=>
BA/F3	MnPHS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NFPPeYk4OiCqcoO=		NX3k[\|dsUW6qaXLpeIlwdiCxZjDLSHIhMHWwa37ve44hd3KrZ3nuLUB1emGwc3\lZ5Rm\CCrbjDtc5V{\SCEQT;GN{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHPlcIwh\3Kxd4ToJIlv[3WkYYTl[EBnd3JiN{KgbJJ{KGK7IF3UV{Bie3OjeTygS2k2OCB;IECuNVE1KM7:TT6=	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODJyNES0NUc,OzB{MES0OFE9N2F-
GISTT1	NVHzb\|J3S3m2b4TvfIlkcXS7IHHzd4F6		M{ntOFczKGi{cx?=		NIjrXY5EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBIUVOWVEGgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA4OiCqcoOgZpkhS2WubGTpeIVzT2yxIHHzd4F6NCCJSUWwJF0hOC5zMzFOwG0v	NHTvT3g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEm5NVQ3PSd-Mki5PVE1PjV:L3G+
BA/F3	M2nCemdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M3vFclczKGi{cx?=		NVPLfnA5UW6qaXLpeIlwdiCxZjDLbZQh\XixbjCxNUBl\WyndHnvckApPTV5IITvJFU2QCC{ZYPp[JVmeyliYX7kJHY3PTSDIH31eIFvfCBqdX7rco94diCxcnnnbY4qKHS{YX7z[oVkfGWmIHnuJI1wfXOnIFLBM2Y{KGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[gZ4VtdCCpcn;3eIghcW6ldXLheIVlKG[xcjC3NkBpenNiYomgUXRUKGG\|c3H5MEBIUTVyIE2gNE4zOzFizszNMi=>	M1fhPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMkC0OFQyLz5\|MEKwOFQ1OTxxYU6=
BA/F3	MULHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NXqzZ2F5PzJiaILz		MWnJcohq[mm2aX;uJI9nKEurdDDlfI9vKDFzIHTlcIV1cW:wIDi1OVchfG9iNUW4JJJme2mmdXXzLUBidmRiREixOmghdXW2YX70JEh2dmuwb4fuJI9zcWerbjmgeJJidnOoZXP0[YQhcW5ibX;1d4UhSkFxRkOgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iClZXzsJIdzd3e2aDDpcoN2[mG2ZXSg[o9zKDd{IHjyd{BjgSCPVGOgZZN{[XluIFfJOVAhRSByLkK5JO69VS5?	NFvldXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEKwOFQ1OSd-M{CyNFQ1PDF:L3G+
GISTT1	NH\QVVVEgXSxdH;4bYNqfHliYYPzZZk>		MVi3NkBpenN?		NI\nRmxEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBIUVOWVEGgZ4VtdHNiaHHyZo9zcW6pIFvJWEBVPjdySTDteZRidnRiYYPz[ZN{\WRiYYOgZ4VtdCCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA4OiCqcoOgZpkhS2WubGTpeIVzT2yxIHHzd4F6NCCJSUWwJF0hOC5\|ODFOwG0v	NX\jWoRHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5PVE1PjVpPkK4PVkyPDZ3PD;hQi=>
BA/F3	NFXTT5pIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M2nEWFczKGi{cx?=		NEfSTpdKdmirYnn0bY9vKG:oIGDES2ZT[WyyaHGgWlU3OURxREi0NnYhdXW2YX70JEh2dmuwb4fuJI9zcWerbjmgeJJidnOoZXP0[YQhcW5ibX;1d4UhSkFxRkOgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iClZXzsJIdzd3e2aDDpcoN2[mG2ZXSg[o9zKDd{IHjyd{BjgSCPVGOgZZN{[XluIFfJOVAhRSByLkWyNkDPxE1w	NIDINlE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEKwOFQ1OSd-M{CyNFQ1PDF:L3G+
BA/F3	MoXnS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NGHFeoM4OiCqcoO=		MX7Jcohq[mm2aX;uJI9nKEurdDDWOVYxTC:YNkW0RUBufXSjboSgLJVvc26xd36gc5Jq\2mwKTD0doFve2[nY4Tl[EBqdiCvb4Xz[UBDSS:IMzDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGOnbHyg[5Jwf3SqIHnuZ5Vj[XSnZDDmc5IhPzJiaILzJIJ6KE2WUzDhd5NigSxiR1m1NEA:KDBwNUS5JO69VS5?	NIjjbFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEKwOFQ1OSd-M{CyNFQ1PDF:L3G+
BA/F3	NVr6fFJ6T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MonNO\|IhcHK\|		M4e3OWlvcGmkaYTpc44hd2ZiS3n0JIV5d25iOTDBXVUxOiC2bzC1NFMhcW6\|ZYL0bY9vKGGwZDDEPFE3KG23dHHueEApfW6tbn;3ckBwemmpaX6pJJRz[W6\|ZnXjeIVlKGmwIH3veZNmKEKDL1[zJINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiY3XscEBoem:5dHigbY5kfWKjdHXkJIZweiB5MjDodpMh[nliTWTTJIF{e2G7LDDHTVUxKD1iMD64N\|Mh\|ryPLh?=	MmjpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB{MES0OFEoRjNyMkC0OFQyRC:jPh?=
BA/F3	M2Cwcmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MUe3NkBpenN?		MWXJcohq[mm2aX;uJI9nKEurdDDWOVYxTC:GOEG2TEBufXSjboSgLJVvc26xd36gc5Jq\2mwKTD0doFve2[nY4Tl[EBqdiCvb4Xz[UBDSS:IMzDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGOnbHyg[5Jwf3SqIHnuZ5Vj[XSnZDDmc5IhPzJiaILzJIJ6KE2WUzDhd5NigSxiR1m1NEA:KDBwOEO0JO69VS5?	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODJyNES0NUc,OzB{MES0OFE9N2F-
BA/F3	M1rvb2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MlnQO\|IhcHK\|		NFjh[XNKdmirYnn0bY9vKG:oIFvpeEBmgG:wIEGxJIRmdGW2aX;uJEg2PjBidH:gOVc5KHKnc3nkeYV{MSCvdYThcpQhMHWwa37ve44hd3KrZ3nuLUB1emGwc3\lZ5Rm\CCrbjDtc5V{\SCEQT;GN{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHPlcIwh\3Kxd4ToJIlv[3WkYYTl[EBnd3JiN{KgbJJ{KGK7IF3UV{Bie3OjeTygS2k2OCB;IECuPVQ{KM7:TT6=	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODJyNES0NUc,OzB{MES0OFE9N2F-
BA/F3	M1vhc2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NUTTVo14PzJiaILz		Ml\zTY5pcWKrdHnvckBw\iCNaYSg[ZhwdiB7IFHZOVAzKHSxIEWwN{BqdnOncoTpc44h[W6mIG[2OVQhdXW2YX70JEh2dmuwb4fuJI9zcWerbjmgeJJidnOoZXP0[YQhcW5ibX;1d4UhSkFxRkOgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iClZXzsJIdzd3e2aDDpcoN2[mG2ZXSg[o9zKDd{IHjyd{BjgSCPVGOgZZN{[XluIFfJOVAhRSBzLkK3JO69VS5?	NFrkS5g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEKwOFQ1OSd-M{CyNFQ1PDF:L3G+
GISTT1	MXjDfZRwfG:6aXPpeJkh[XO\|YYm=		NInlWJI4OiCqcoO=		MYfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDHTXNVXDFiY3XscJMhcGG{Yn;ybY5oKEuLVDDEPFE3TSCvdYThcpQh[XO\|ZYPz[YQh[XNiY3XscEBoem:5dHigbY5pcWKrdHnvckBi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyS4xwKGG\|c3H5MEBIUTVyIE2gNU4{PSEQvF2u	M2D5fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUmxOFY2Lz5{OEm5NVQ3PTxxYU6=
BA/F3	NV3ncG9KT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M{\yXVczKGi{cx?=		M1i0VWlvcGmkaYTpc44hd2ZiS3n0JGQ5OT[YIH31eIFvfCBqdX7rco94diCxcnnnbY4qKHS{YX7z[oVkfGWmIHnuJI1wfXOnIFLBM2Y{KGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[gZ4VtdCCpcn;3eIghcW6ldXLheIVlKG[xcjC3NkBpenNiYomgUXRUKGG\|c3H5MEBIUTVyIE2gNk4{PzFizszNMi=>	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODJyNES0NUc,OzB{MES0OFE9N2F-
GIST430	MYLDfZRwfG:6aXPpeJkh[XO\|YYm=		NUjqWGRmPzJiaILz		MlLUR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gS2lUXDR\|MDDj[YxteyCqYYLic5JqdmdiS1nUJHY3PTSDIH31eIFvfCCjc4Pld5Nm\CCjczDj[YxtKGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFczKGi{czDifUBE\WyuVHn0[ZJIdG9iYYPzZZktKEeLNUCgQUA{KM7:TT6=	NVHrVY12RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5PVE1PjVpPkK4PVkyPDZ3PD;hQi=>
BA/F3	Mn:5R5l1d3SxeHnjbZR6KGG\|c3H5		NYX6OVVEPzJiaILz		NFXBTHdEgXSxdH;4bYNqfHliaX6gcY92e2VicHHy[Y51[WxiQlGvSlMh[2WubIOgbY5kfWKjdHXkJIZweiB5MjDodpMh[nliTWTTJIF{e2G7LDDHTVUxKD1iOT65OVMh\|ryPLh?=	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODJyNES0NUc,OzB{MES0OFE9N2F-
U-2 OS	MX3xTHRUKGG\|c3H5				NXnXU\|dOeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGWtNkBQWyClZXzsdy=>	Mn\FQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
A673	MXTxTHRUKGG\|c3H5				NWjaZ2R{eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFG2O\|Mh[2WubIO=	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
DAOY	NHTFfJhyUFSVIHHzd4F6				NE\UeGxyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiRFHPXUBk\Wyucx?=	M1vFT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Saos-2	M3XJO5FJXFNiYYPzZZk>				M3rrSpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVYX;zMVIh[2WubIO=	MoTxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
BT-37	MVTxTHRUKGG\|c3H5				M4rhVpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2zO{Bk\Wyucx?=	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
RD	M2nm[5FJXFNiYYPzZZk>				NGfMTlhyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUlSgZ4VtdHN?	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
BT-12	Ml62dWhVWyCjc4PhfS=>				M3flbZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2xNkBk\Wyucx?=	M{nDclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
MG 63 (6-TG R)	MYrxTHRUKGG\|c3H5				MVjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVUdiNkOgLFYuXEdiUjmgZ4VtdHN?	M{LEOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB1643	NUfWOFJ1eUiWUzDhd5NigQ>?				NUOzR3p7eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF7CNVY1OyClZXzsdy=>	NIG5N\|Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
OHS-50	NI\lWZFyUFSVIHHzd4F6				MXjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhV0iVLUWwJINmdGy\|	M3nKblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SJ-GBM2	NFH6OZlyUFSVIHHzd4F6				MXvxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0pvR1LNNkBk\Wyucx?=	NIXISWo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-MC	MY\xTHRUKGG\|c3H5				NH3wV5ByUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1OSyClZXzsdy=>	NEm1dHA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
NB-EBc1	MoHBdWhVWyCjc4PhfS=>				NHHPfHVyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKtSWJkOSClZXzsdy=>	M1K3blxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
LAN-5	M3qwR5FJXFNiYYPzZZk>				NHP1[HRyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTFHOMVUh[2WubIO=	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh18	NUTOU3ZueUiWUzDhd5NigQ>?				M3TpdpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaEG4JINmdGy\|	NFTQ[lA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	PUMA / p53; PubMed: 24763611 Clin Cancer Res WT and p53-KO HCT116 cells were treated with 40 μmol/L regorafenib for 24 hours. PUMA expression was analyzed by Western blotting. Bim / Bid / Bak / Bcl-Xl / Mcl-1; PubMed: 24763611 Clin Cancer Res The expression of indicated Bcl-2 family members was analyzed by Western blotting in HCT116 cells treated with 40 μmol/L regorafenib at indicated time points. p-p65(S536) / p65; PubMed: 24763611 Clin Cancer Res HCT116 cells were treated with 40 μmol/L regorafenib. Expression of p-p65 (S536) and β-actin at indicated time points was analyzed by Western blotting. p-FGFR2 / p-FRS2α / p-AKT / p-MAPK / p-P90RSK / FGFR2 / AKT / MAPK / p90RSK; PubMed: 29573334 Mol Oncol Changes in FGFR2 signaling molecules after regorafenib treatment. Immunoblotting assays were performed after treatment with increasing concentrations of regorafenib for 24 h. Cyclin D / Cyclin E / Cyclin A / Cyclin B / p27 / p21; PubMed: 29573334 Mol Oncol Changes in cell cycle and/or apoptosis‐related molecules. p-STAT3 / STAT3 / PARP / Caspase-9; PubMed: 25071018 Oncotarget p-STAT3(Tyr705), STAT3, the cleaved fragments of PARP and the cleaved fragments of caspase-9 were measured by western blotting at the times indicated after Hct-15 and DLD1 cells were treated with regorafenib at 5 μM. β-actin was used as a loading control. The cleaved fragments of PARP and the cleaved fragments of caspase-9 were indicated by arrows.	24763611 29573334 25071018
Immunofluorescence	p65; PubMed: 24763611 Clin Cancer Res HCT116 cells were treated with 40 μmol/L regorafenib for 3 hours and then fixed. Immunofluorescence was carried out as described in the Materials and Methods for p65 (green) and DAPI (blue). Representative pictures (400×) are shown. Arrows indicate cells with p65 nuclear translocation. F-actin / Vimentin / E-cadherin ; PubMed: 27580057 Oncotarget Immunofluorescence microscopy analysis of rhodamine phalloidin-stained F-actin, DAPI-stained nuclei, vimentin and E-cadherin in the cells.	24763611 27580057
Growth inhibition assay	GI50; PubMed: 29573334 Mol Oncol Screening of in vitro sensitivity to regorafenib in 14 gastric and 10 colorectal cancer cell lines. MTT cell proliferation assays were performed with increasing concentrations of regorafenib for 72 h. GI 50 values were averaged from at least three independent experiments in hexaplicate. Cell viability; PubMed: 25071018 Oncotarget MTT assay was performed to measure the cell viability in the colon cancer cell lines 2 days after treatment with regorafenib in a dose-dependent manner.	29573334 25071018

In vivo

Regorafenib reveals potent dose-dependent TGI in various preclinical human xenograft models in mice, with tumor shrinkages in breast MDA-MB-231 and renal 786-O carcinoma models. Regorafenib prevents not only the growth of syngeneic primary 4T1 breast tumors growing orthotopically in the fat pad, but also suppresses the formation of tumor metastasis in the lung. ^[1]

Protocol

Kinase Assay:^[1]	- Collapse Kinase assays: In vitro assays using recombinant VEGFR2 (murine aa785–aa1367), VEGFR3 (murine aa818–aa1363), PDGFRβ (aa561–aa1106), Raf-1 (aa305–aa648) and BRafV600E (aa409–aa765) kinase domains are performed. Initial in vitro kinase inhibition profiling is performed at a fixed 1 μM Regorafenib concentration. Inhibitory concentration of 50% (IC50) values are determined from selected responding kinases, e.g., VEGFR1 and RET. TIE2 kinase inhibition is measured with a homogeneous time-resolved fluorescence (HTRF) assay using a recombinant fusion protein of glutathione-S-transferase, the intracellular domain of TIE2 and the peptide biotin-Ahx-EPKDDAYPLYSDFG as substrate.
Cell Research:^[1]	- Collapse Cell lines: GIST 882 and TT cells Concentrations: 5 nM-10 μM Incubation Time: 96 hours Method: For proliferation assays, GIST 882 and TT cells are grown in RPMI medium containing L-glutamine, and MDA-MB-231, HepG2 and A375 cells in DMEM always containing 10% hiFBS. Cells are trypsinized, plated at 5×104 cells/well in 96-well plates in complete media containing 10% FBS and grown overnight at 37 °C. The next day, vehicle or Regorafenib serially diluted in complete growth media to between 10 μM and 5 nM final concentrations, and 0.2% DMSO, is added and incubation is continued for 96 hours. Cell proliferation is quantified. (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: Female athymic NCr nu/nu mice with Colo-205, MDA-MB-231 or 786-O Dosages: 3 mg/kg, 10 mg/kg, 30 mg/kg, 100 mg/kg Administration: Orally (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	97 mg/mL (200.9 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Regorafenib (BAY 73-4506) SDF

Molecular Weight	482.82
Formula	C₂₁H₁₅ClF₄N₄O₃
CAS No.	755037-03-7
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	Fluoro-Sorafenib, Resihance, Stivarga
Smiles	CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-05-17)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04476329	Recruiting	Drug: Regorafenib 40 MG	Hepatocellular Carcinoma	SC Liver Research Consortium LLC\|Bayer	January 21 2021	Phase 2
NCT03793361	Recruiting	Drug: Regorafenib\|Drug: Placebo	Metastatic Soft Tissue Sarcoma	Centre Oscar Lambret	May 15 2019	Phase 2
NCT03386825	Completed	Drug: Regorafenib (Stivarga BAY73-4506)	Colorectal Neoplasms	Bayer	January 31 2018	--
NCT03042689	Active not recruiting	Drug: Regorafenib	Acute Myeloid Leukemia	Massachusetts General Hospital\|Bayer	April 17 2017	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
How to resuspend Regorafenib for in vivo studies?
Answer:
For in vivo study, we recommend to use 2% DMSO+30% PEG 300+5% Tween 80+ddH2O up to 5mg/ml.

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

Selective VEGFR Inhibitors

Vandetanib (ZD6474) : VEGFR2-selective, IC50=40 nM.
Most Potent VEGFR Inhibitor

Cabozantinib (XL184, BMS-907351) : VEGFR2, IC50=0.035 nM.
FDA-approved VEGFR Inhibitor

Axitinib : Approved by FDA for Renal Cell Carcinoma.
Classic VEGFR Inhibitor

Nintedanib (BIBF 1120) : Potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50 of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM. Phase 3.

Related VEGFR Products

SU5402 ^New

SU5402 is a potent multi-targeted receptor tyrosine kinase inhibitor with IC50 of 20 nM, 30 nM, and 510 nM for VEGFR2, FGFR1, and PDGF-Rβ, respectively.
Erlotinib (OSI-774) ^New

Erlotinib (OSI-774, CP358774, NSC 718781, Tarceva) is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. Erlotinib induces autophagy.
Bemcentinib (R428) ^New

Bemcentinib (R428, BGB324) is an inhibitor of Axl with IC50 of 14 nM, >100-fold selective for Axl versus Abl. Selectivty for Axl is also greater than Mer and Tyro3 (50-to-100- fold more selective) and InsR, EGFR, HER2, and PDGFRβ (100- fold more selective).
Axitinib (AG 013736)

Axitinib (AG 013736) is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM in Porcine aorta endothelial cells, respectively.

Features:Superior as second-line therapy relative to sorafenib (current standard-of-care).
Cabozantinib (BMS-907351)

Cabozantinib (XL184, BMS-907351) is a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM in cell-free assays, respectively. Cabozantinib induces PUMA-dependent apoptosis in colon cancer cells via AKT/GSK-3β/NF-κB signaling pathway.
Nintedanib (BIBF 1120)

Nintedanib (BIBF 1120, Intedanib, Vargatef, Ofev) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50 of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM in cell-free assays. Phase 3.
Vandetanib (ZD6474)

Vandetanib (ZD6474) is a potent inhibitor of VEGFR2 with IC50 of 40 nM in a cell-free assay. It also inhibits VEGFR3 and EGFR with IC50 of 110 nM and 500 nM, respectively. Not sensitive to PDGFRβ, Flt1, Tie-2 and FGFR1 with IC50 of 1.1-3.6 μM. No activity against MEK, CDK2, c-Kit, erbB2, FAK, PDK1, Akt and IGF-1R with IC50 above 10 μM. Vandetanib (ZD6474) increases apoptosis and induces autophagy by increasing the level of reactive oxygen species (ROS).
Lenvatinib (E7080)

Lenvatinib (E7080) is a multi-target inhibitor, mostly for VEGFR2(KDR)/VEGFR3(Flt-4) with IC50 of 4 nM/5.2 nM, less potent against VEGFR1/Flt-1, ~10-fold more selective for VEGFR2/3 against FGFR1, PDGFRα/β in cell-free assays. Lenvatinib (E7080) also inhibits FGFR1-4, PDGFR, Kit (c-Kit), RET (c-RET), and shows potent antitumor activities. Phase 3.
Pazopanib

Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms/CSF1R with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively. Pazopanib induces cathepsin B activation and autophagy.
Pazopanib HCl (GW786034 HCl)

Pazopanib HCl (GW786034 HCl) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively. Pazopanib induces autophagic Type II cell death.

Features:A multi-kinase inhibitor.

Choose Your Country or Region

By Signaling Pathways

By product type

Regorafenib (BAY 73-4506)